TLDR:
- Boston/Cambridge tops the list of U.S. biopharma clusters for 2024, surpassing San Francisco in venture capital financing.
- Consistent top regions found to have early investment, scientific excellence, robust networks, and diverse business ecosystems.
In the study by European academics, the top 10 U.S. biomedical and pharma clusters for 2024 were analyzed, with Boston/Cambridge, MA reclaiming the top spot. This region excels in NIH funding, laboratory space, venture capital investment, and patents. San Francisco Bay Area ranked second, with strong innovation capabilities and ample financial support, despite facing job cuts. The BioHealth Capital Region, spanning Maryland, Virginia, and Washington, D.C., retained its third position with notable developments and investments. New York/New Jersey showcased impressive growth with major projects and high job numbers, while San Diego benefited from substantial venture capital and new developments. Each region demonstrated unique strengths and ongoing advancements in the U.S. biomedical and pharma sectors.
